According to a new study published in JAMA Internal Medicine, women in the U.S. are now projected to live about six years longer than U.S. men. TIME reports: [T]he 2021 data represent the largest gender-based life expectancy gap in the U.S. since 1996. The gulf began to widen before the COVID-19 pandemic, the authors note, but the trend accelerated from 2019 to 2021. Deaths from COVID-19 and unintentional injuries, a category that includes accidental drug overdoses, were the largest contributors to the widening of the gap, but differential rates of homicide, heart disease, and suicide deaths also played a role, according to the report. It's well-established that men die of these causes more frequently than women, and in recent years, they have been some of the most common causes of death overall. Heart disease, COVID-19, and unintentional injuries accounted for three of the top five in 2021.

The gender gap would have been even wider, the authors note, but for factors including increases in maternal mortality and decreases in cancer deaths among men. Overall, the data underscore the continued importance of limiting COVID-19's spread, and of finding better ways to improve national mental health and prevent drug overdoses and suicides -- fatalities sometimes labeled by experts as "deaths of despair."

Doctors have long relied on a few key patient characteristics to assess risk of a heart attack or stroke, using a calculus that considers blood pressure, cholesterol, smoking and diabetes status, as well as demographics: age, sex and race. Now, the American Heart Association is taking race out of the equation. From a report: The overhaul of the widely used cardiac-risk algorithm is an acknowledgment that, unlike sex or age, race identification in and of itself is not a biological risk factor. The scientists who modified the algorithm decided from the start that race itself did not belong in clinical tools used to guide medical decision making, even though race might serve as a proxy for certain social circumstances, genetic predispositions or environmental exposures that raise the risk of cardiovascular disease.

The revision comes amid rising concern about health equity and racial bias within the U.S. health care system, and is part of a broader trend toward removing race from a variety of clinical algorithms. "We should not be using race to inform whether someone gets a treatment or doesn't get a treatment," said Dr. Sadiya Khan, a preventive cardiologist at Northwestern University Feinberg School of Medicine, who chaired the statement writing committee for the American Heart Association, or A.H.A. The statement was published on Friday [PDF] in the association's journal, Circulation. An online calculator using the new algorithm, called PREVENT, is still in development.

Britain's drugs regulator has approved a groundbreaking treatment for two painful and debilitating lifelong blood disorders, which works by "editing" the gene that causes them. From a report: The Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light for Casgevy to be used to treat sickle cell disease and beta thalassemia. It is the first medicine licensed anywhere that works by deploying gene editing that uses the "genetic scissors," known as CRISPR, for which its inventors won the Nobel prize for chemistry.

Casgevy's developers hope the pioneering treatment could banish the pain, infections and anaemia sickle cell disease brings and the severe anaemia experienced by those with beta thalassemia. About 15,000 people in the UK, almost all of African or Caribbean heritage, have sickle cell disease. About 1,000 -- mainly of Mediterranean, south Asian, south-east Asian and Middle Eastern background -- have beta thalassemia and need regular blood transfusions to treat their anaemia. Experts in the illnesses hope Casgevy may be a cure, making it no longer necessary for people with the conditions to have a bone marrow transplant. Until now this has been the only treatment available, even though the body can reject the donor marrow. The Sickle Cell Society welcomed the MHRA's decision as a "historic moment for the sickle cell community" which "offers [them] newfound hope and optimism."

An anonymous reader quotes a report from NBC News: A prolonged decline in male fertility in the form of sperm concentrations appears to be connected to the use of pesticides, according to a study published Wednesday. Researchers compiled, rated and reviewed the results of 25 studies of certain pesticides and male fertility and found that men who had been exposed to certain classes of pesticides had significantly lower sperm concentrations. The study, published Wednesday in Environmental Health Perspectives, included data from more than 1,700 men and spanned several decades. "No matter how we looked at the analysis and results, we saw a persistent association between increasing levels of insecticide and decreases in sperm concentration," said study author Melissa Perry, who is an environmental epidemiologist and the dean of the College of Public Health at George Mason University. "I would hope this study would get the attention of regulators seeking to make decisions to keep the public safe from inadvertent, unplanned impacts of insecticides." [...]

Scientists have long suspected changes to the environment could be contributing, and they've been probing the role of pesticides for decades in studies of animals and in human epidemiology research. The new analysis focuses on two groups of chemicals -- organophosphates and some carbamates -- that are commonly used in insecticides. The researchers looked at data collected from groups of people with exposures to pesticides and others who were not. Most, but not all, of the research centered on exposures in the workplace. The researchers controlled for outside factors that could contribute to lower sperm counts like smoking and age. Perry said researchers aren't sure how pesticides are affecting sperm concentrations and more research will be needed.

It's likely that pesticides are one of many environmental factors that could be contributing to a decline in sperm concentrations. The trend of sperm concentration declines has been widely observed in studies around the world, but it's a complicated topic and some scientists still have reservations. Sperm are notoriously difficult to count and the technology to do so has changed over the years. There are many confounding factors that can affect male fertility, including age, obesity and opioid use, to name a few. Sperm concentrations are one important data point to consider, but other factors -- like how sperm are shaped and how they swim -- are also critical to male fertility. Perry said she hopes agencies like the Environmental Protection Agency begin to factor the impact of chemicals and pesticides on reproductive health in their assessments. "Given the body of evidence and these consistent findings, it's time to proactively reduce these insecticide exposures for men wanting to have families," Perry said.

Amazon said on Wednesday that it was removing seven eyedrops products from its website after the Food and Drug Administration warned the company that the eyedrops had not been recognized as safe and effective. From a report: The F.D.A. said in a letter to Andrew Jassy, Amazon's chief executive, on Monday that Amazon had violated federal regulations by selling the eyedrops, which claimed to help with problems including pink eye, dry eyes, eyestrain and floaters. "These products are especially concerning from a public health perspective," the F.D.A. letter said. "Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body's natural defenses."

The eyedrops named in the letter are: Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief, and Manzanilla Sophia Chamomile Herbal Eye Drops. None of the eyedrops appeared to be available for purchase on Amazon on Wednesday morning. The company said in an emailed statement on Wednesday that "safety is a top priority."

AI could be used to predict if a person is at risk of having a heart attack up to 10 years in the future, a study has found. From a report: The technology could save thousands of lives while improving treatment for almost half of patients, researchers at the University of Oxford said. The study, funded by the British Heart Foundation (BHF), looked at how AI might improve the accuracy of cardiac CT scans, which are used to detect blockages or narrowing in the arteries.

Prof Charalambos Antoniades, chair of cardiovascular medicine at the BHF and director of the acute multidisciplinary imaging and interventional centre at Oxford, said: "Our study found that some patients presenting in hospital with chest pain -- who are often reassured and sent back home -- are at high risk of having a heart attack in the next decade, even in the absence of any sign of disease in their heart arteries. Here we demonstrated that providing an accurate picture of risk to clinicians can alter, and potentially improve, the course of treatment for many heart patients."

About 350,000 people in the UK have a CT scan each year but, according to the BHF, many patients later die of heart attacks due to their failure in picking up small, undetectable narrowings. Researchers analysed the data of more than 40,000 patients undergoing routine cardiac CT scans at eight UK hospitals, with a median follow-up time of 2.7 years. The AI tool was tested on a further 3,393 patients over almost eight years and was able to accurately predict the risk of a heart attack. AI-generated risk scores were then presented to medics for 744 patients, with 45% having their treatment plans altered by medics as a result.

There's already a powerful immunotherapy that "involves engineering a patient's T cells so they recognize and attack cancer cells," writes one of America's top cancer hospitals. The Memorial Sloan Kettering Cancer Center notes that CAR T cell therapy has already begun to revolutionize cancer treatment," with these "chimeric" T cells "multiplied in a lab and given back to the patient to be a continual fighting force against the cancer."

But now "New research from the lab of physician-scientist Michel Sadelain, MD, PhD, shows that disrupting a single gene in the CAR T cells can make them more potent and able to fight tumors longer." In a paper published in Cancer Discovery, the team demonstrated that disrupting the gene SUV39H1 causes a ripple effect: It restores the expression of multiple genes that help sustain the T cells' longevity. The researchers showed that this approach improved CAR T cell effectiveness against multiple cancers in mice...

The researchers used the gene-editing tool CRISPR/Cas9 to alter SUV39H1 in human CAR T cells. They placed these modified CAR T cells into mice that had been implanted with either human leukemia cells or prostate cancer cells. For both cancers, the CAR T cells were able to sustain their function without becoming exhausted, leading to tumor elimination. By contrast, mice with unedited CAR T cells did not survive the cancer. "The edited CAR T cells can maintain their anti-cancer effects, even when we challenged them repeatedly by exposing them to new tumors over time," Dr. Zhao says. "These results suggest that SUV39H1-edited CAR T cells may reduce tumor relapse in patients."

There did not appear to be serious side effects in the mice, although researchers will need to confirm the safety of this approach in humans. The biotechnology company Mnemo Therapeutics is exploring the possibility of conducting clinical trials based on this research.

Cells have a protein receptor that will cause that cell to die — in theory. Unfortunately, "Previous efforts to target this receptor have been unsuccessful," says Jogender Tushir-Singh, an associate professor in the Department of Medical Microbiology and Immunology at the University of California, Davis.

But he's now led a team of researchers at the university's Comprehensive Cancer Center that's identified a receptor-activating protein section. And more importantly, "now that we've identified this epitope, there could be a therapeutic path forward" for targeting that receptor... in tumors. The findings were published Oct. 14 in the Nature journal Cell Death & Differentiation... Death receptors do precisely what their name implies — when targeted, they trigger programmed cell death of tumor cells. They offer a potential workaround that could simultaneously kill tumor cells and pave the way for more effective immunotherapies and CAR T-cell therapy...

Tushir-Singh and his colleagues knew they might be able to target cancer cells selectively if they found the right epitope. Having identified this specific epitope, he and other researchers can now design a new class of antibodies to selectively bind to and activate Fas to potentially destroy tumor cells specifically.
Singh says their research "sets the stage" to develop antibodies that selectively kill tumor cells.

A new book argues lockdowns during the pandemic were "a failure." But in response CNN published an opinion piece disagreeing — written by physician/infectious disease expert Kent Sepkowitz from the Memorial Sloan Kettering Cancer Center in New York — who argues "You bet it was worth it." [Authors Joe Nocera and Bethany McLean] consider the lockdown a single activity stretched across the entire pandemic; in contrast, I would distinguish the initial lockdown, which was crucial, from the off-and-on lockdowns as therapies, vaccines and overall care improved. There is an argument to be made that these were not anywhere near as effective... One only had to work in health care in New York City to see the difference between early 2020, when the explosion of cases overwhelmed the city, versus later in 2020 when an effective therapy had been identified, supplies and diagnostic testing had been greatly improved (though still completely inadequate) and the makeshift ICUs and emergency rooms had been set in place. It was still a nightmare to be sure, but it was a vastly more organized nightmare.

The "short-term benefits" at the start of the pandemic are simple to characterize: Every infection that was delayed due to the lockdowns was a day to the good, a day closer to the release of the mRNA vaccines in December 2020, a less-hectic day for the health care workers, a day for clinical trials to mature. Therefore, the authors' statement that lockdowns "were a mistake that should not be repeated" because they had no "purpose other than keeping hospitals from being overrun in the short-term" is to me a fundamental misunderstanding of the day-to-day work that was being done. Most disturbing to me about this assessment and the others that have come along are the minimal mention of the death and debility the infection caused. A reminder for those who have forgotten just how brutal the pandemic was: Worldwide there have been 7 million deaths. In the U.S., there have been more than a million deaths, millions have some post-infection debility and many health care workers remain profoundly demoralized. [By these figures the U.S., with 4.2% of the world's population, had 14% of Covid fatalities.]

In this context, many of the outcomes of concern listed by Nocera and McLean — suicidal thoughts in teens, alcoholism and drug use increases, violence — are as easily explained by this staggering death toll as by the cabin fever brought on by lockdowns. Once again: About 1 out of every 350 Americans died in the Covid-19 pandemic. Another way to consider the impact of so many deaths is examination of life expectancy. Of note, life expectancy in the U.S. fell in 2020 (1.8 years) and 2021 (0.6 years), the sharpest drop since the 1920s; per the US Centers for Disease Control and Prevention, 74% of the drop was attributed to Covid-19... To fall more than two years so precipitously requires the deaths of many in their 30s and 40s and 50s, as occurred with the first year of the pandemic.

An anonymous reader quotes a report from Scientific American: This week doctors announced they had completed the first successful transplant of a partial face and an entire eye. In May at NYU Langone Health in New York City, the surgery was performed on a 46-year-old man who had suffered severe electrical burns to his face, left eye and left arm. He does not yet have vision in the transplanted eye and may never regain it there, but early evidence suggests the eye itself is healthy and may be capable of transmitting neurological signals to the brain. The feat opens up the possibility of restoring the appearance -- and maybe even sight -- of people who have been disfigured or blinded by injuries. Researchers caution there are many technical hurdles before such a procedure can effectively treat vision loss, however.

"I think it's an important proof of principle," says Jeffrey Goldberg, a professor and chair of ophthalmology at the Byers Eye Institute at Stanford University, who was not involved in the surgery but has been part of a team working toward whole-eye transplants in humans. "I think it points to the opportunity and importance that we really stand on the verge of being able to [achieve] eye transplants and vision restoration for blind patients more broadly."But he cautions that the main obstacle is achieving regeneration of the optic nerve, which carries visual signals from the retina to the brain; this step has not yet been successfully demonstrated in humans.

Scientists have been working toward whole-eye transplantation for many years. "This has been, I would say, science fiction for a long time," says Jose-Alain Sahel, a professor and chair of the department of ophthalmology at the University of Pittsburgh School of Medicine, who has been working toward such transplants with Goldberg and others. Progress in surgical techniques and nerve regeneration have made this goal seem more attainable. [...] "The fact that this surgery was successful is wonderful news," Sahel says. He cautions that surgery is only a small part of the issues that need to be addressed in order to restore eye function, however. These include making sure the immune system doesn't reject the donor eye, which is a challenge with any type of transplant. Then the corneal nerve -- which carries sensory signals from the transparent part of the eye -- must be reconnected. Yet the most complex part is regenerating the optic nerve. In order to do so, surgeons have to coax the nerve fibers to grow to the right place, which Sahel says could take months or even years. And complete optic nerve regeneration has not yet been successfully achieved in humans or other mammals.

Long-time Slashdot reader Alain Williams writes: Apple co-founder Steve Wozniak is in the hospital in Mexico, according to multiple reports.

It is not currently clear what the cause is. The 73-year-old was in Mexico City attending the World Business Forum (WBF), a business conference. [According to TMZ, Wozniak finished his speech but then told his wife he was "feeling strange." She reportedly insisted he go to the hospital.] An unnamed source from the WBF said that Mr Wozniak fainted on Wednesday at the event [minutes before his participation], according to CNN. TMZ reports that Wozniak was hospitalized after "suffering what appears to be vertigo." Mexican media outlets were reporting that it was due to a possible stroke.

An anonymous reader quotes a report from the Financial Times: Amazon Prime members will be able to access US healthcare provider One Medical's suite of benefits, for a fee, as the ecommerce company looks to expand its presence in the $4 trillion American healthcare industry. Prime members in the US who opt in will have access to unlimited, on-demand virtual healthcare via One Medical, the subscription-based group that Amazon acquired last year for $3.9 billion. They will also be able to schedule in-person appointments that they will either pay for themselves or that will be covered by insurance.

The addition to Amazon's flagship Prime membership program comes as the company looks to "stack" healthcare services together and broaden its reach in the sector, which would be "big for us if we do a good job," said Neil Lindsay, senior vice-president of Amazon Health. The subscription will cost Amazon Prime members $9 per month or $99 per year, compared with the standard One Medical subscription fee of $199 per year. That will come on top of the $139 per year, or $14.99 a month, price for a Prime subscription.

The move is Amazon's latest effort to leverage its loyal base of Prime members and become a big player in the healthcare industry. In January, following its 2018 acquisition of mail-order pharmacy PillPack for about $1 billion, Amazon launched RxPass, which allows Prime members to order an unlimited amount of some unbranded prescription medications for $5 a month. It has also rolled out a "Clinic" telehealth service that connects patients with clinicians and a broader mail-order pharmacy service.

The scientific literature is polluted with fake manuscripts churned out by paper mills -- businesses that sell bogus work and authorships to researchers who need journal publications for their CVs. But just how large is this paper-mill problem? From a report: An unpublished analysis shared with Nature suggests that over the past two decades, more than 400,000 research articles have been published that show strong textual similarities to known studies produced by paper mills. Around 70,000 of these were published last year alone. The analysis estimates that 1.5-2% of all scientific papers published in 2022 closely resemble paper-mill works. Among biology and medicine papers, the rate rises to 3%.

Without individual investigations, it is impossible to know whether all of these papers are in fact products of paper mills. But the proportion -- a few per cent -- is a reasonable conservative estimate, says Adam Day, director of scholarly data-services company Clear Skies in London, who conducted the analysis using machine-learning software he developed called the Papermill Alarm. In September, a cross-publisher initiative called the STM Integrity Hub, which aims to help publishers combat fraudulent science, licensed a version of Day's software for its set of tools to detect potentially fabricated manuscripts.

Paper-mill studies are produced in large batches at speed, and they often follow specific templates, with the occasional word or image swapped. Day set his software to analyse the titles and abstracts of more than 48 million papers published since 2000, as listed in OpenAlex, a giant open index of research papers that launched last year, and to flag manuscripts with text that very closely matched known paper-mill works. These include both retracted articles and suspected paper-mill products spotted by research-integrity sleuths such as Elisabeth Bik, in California, and David Bimler (also known by the pseudonym Smut Clyde), in New Zealand.

An anonymous reader quotes a report from Motherboard: [A] new tech startup, Prophetic, aims to bring lucid dreams to a much wider audience by developing a wearable device designed to spark the experience when desired. Prophetic is the brainchild of Eric Wollberg, its chief executive officer, and Wesley Louis Berry III, its chief technology officer. The pair co-founded the company earlier this year with the goal of combining technologies, such as ultrasound and machine learning models, "to detect when dreamers are in REM to induce and stabilize lucid dreams" with a device called the Halo according to the company's website. [...]

Prophetic does not make any medical claims about its forthcoming products -- Halo is tentatively slated for a 2025 release -- though Wollberg and Berry both expressed optimism about broader scientific research that suggests lucid dreams can reduce PTSD-related nightmares, promote mindfulness, and open new windows into the mysterious nature of consciousness. To explore those links further, Prophetic has partnered with the Donders Institute, a research center at Radboud University in the Netherlands that is focused on neuroscience and cognition, to generate the largest dataset of electroencephalogram (EEG) and functional magnetic resonance imaging (fMRI) observations of lucid dreamers, according to the company. The collaboration will also explore one of central technologies behind Prophetic's vision, known as transcranial focused ultrasound (TUS). This non-invasive technique uses low-intensity ultrasound pulses to probe the brain, and interact with neural activity, with a depth and precision that cannot be achieved with previous methods, such as transcranial electrical stimulation or transcranial magnetic stimulation.

At this point, both the possibilities and limits of Prophetic's concept remain unclear. While ultrasound devices have been widely used in medicine for decades, the process of stimulating parts of the brain with TUS is a relatively new development. Within the past few years, scientists have shown that TUS "has the potential to be used both as a scientific instrument to investigate brain function and as a therapeutic modality to modulate brain activity," according to a 2019 study, and "could be a useful tool in the treatment of clinical disorders characterized by negative mood states, like depression and anxiety disorders," according to a 2020 study. What is not known, yet, is whether TUS can induce or stabilize lucid dreams, though the Prophetic team is banking on a positive answer to this open question. Its wearable headband prototype, the Halo, was developed with the company Card79 and can currently read EEG data of users. Over the next year, Prophetic aims to use the dataset from their partnership with the Donders Institute to train machine learning models that will stimulate targeted neural activity in users with ultrasound transducers as a means of inducing lucid dreams.

An anonymous reader quotes a report from The Guardian: Marc, 63, from Bordeaux, France, was diagnosed with the degenerative disease more than 20 years ago and had developed severe mobility problems, including balance impairments and freezing of gait. After receiving the implant, which aims to restore normal signaling to the leg muscles from the spine, he has been able to walk more normally and regained his independence. "I practically could not walk any more without falling frequently, several times a day. In some situations, such as entering a lift, I'd trample on the spot, as though I was frozen there, you might say," he said. "Right now, I'm not even afraid of the stairs any more. Every Sunday I go to the lake, and I walk around 6 kilometers [3.7 miles]. It's incredible."

The implant is yet to be tested in a full clinical trial. But the Swiss team, who have a longstanding program to develop brain-machine interfaces to overcome paralysis, hope that their technology could offer an entirely new approach to treating movement deficits in those with Parkinson's disease. "It is impressive to see how by electrically stimulating the spinal cord in a targeted manner, in the same way as we have done with paraplegic patients, we can correct walking disorders caused by Parkinson's disease," said Jocelyne Bloch, neurosurgeon and professor at the CHUV Lausanne University hospital, who co-led the work.

First, the team developed a personalized anatomical map of Marc's spinal cord that identified the precise locations that were involved in signaling to the leg to move. Electrodes were then implanted at these locations, allowing stimulation to be delivered directly into the spine. The patient wears a movement sensor on each leg and when walking is initiated the implant automatically switches on and begins delivering pulses of stimulation to the spinal neurons. The aim is to correct abnormal signals that are sent from the brain, down the spine, to the legs in order to restore normal movement. "At no point is [the patient] controlled by the machine," said Prof Eduardo Martin Moraud, of Lausanne University hospital. "It's just enhancing his capacity to walk." The study, published in Nature Medicine, found that the implant improved walking and balance deficits and when Marc's walking was analyzed it more closely resembled that of healthy controls than that of other Parkinson's patients. Marc also reported significant improvements in his quality of life.

Many Americans want to abolish Daylight Saving Time, reports NBC News: Since 2018, nearly all states have passed or entertained legislation that would drop the twice-a-year time shift. And 19 states have passed laws or resolutions in support of year-round daylight saving time, according to data from the National Conference of State Legislatures. But there's a caveat: Nothing can change until Congress addresses a 1960s-era law blocking such action.
"This ritual of changing time twice a year is stupid," U.S. Senator Marco Rubio said in March, reintroducing legislation to end Daylight Saving Time. In an official statement the Senator announced that "Locking the clock has overwhelming bipartisan and popular support. This Congress, I hope that we can finally get this done."

But according to the Hill, "Both the House and Senate versions of the Sunshine Protection Act of 2023 haven't appeared to go far. The Senate bill has been read twice and referred to a committee, while the House bill has only been referred to a subcommittee."

While America waits, another medical association has come out in favor of ending Daylight Saving Time, reports NBC News: The American Academy of Sleep Medicine is a medical association whose professionals advocate for policies that improve sleep health. On Tuesday, the academy released a statement calling on the U.S. to eliminate daylight saving time completely, stating that standard time best supports health and safety, as it aligns with people's natural circadian rhythm. Undergoing the time switch itself raises the most concerns. Research shows that after the "spring forward" time change, workplace injuries, car crash deaths and heart attack risk have all increased. One 2023 study found that a week after transitioning from the time change, people reported more dissatisfaction with sleep and higher rates of insomnia.

"Software that controls your body should always respect your freedom," warns the program manager of the Free Software Foundation: In July, users of the proprietary software app LibreLink, who live in the UK and use Apple devices, found that the app they depend on to monitor their blood sugar was not working anymore after the developer Abbott pushed an update for the app... Despite what its name may suggest, there is nothing libre about the LibreLink app. It's proprietary software, which means users must depend on the company to keep it running and to distribute it. With free software, [a user] would have had the freedom to run, copy, distribute, study, change, and improve the software himself, or he could have leaned on a community of developers and users to share and fix the software, and the old version of the software would have been available to revert the update...

Two months later, with Apple's update to iOS 17, users of the FreeStyle LibreLink and Libre 2 apps had reason again to fear that the software they rely on wouldn't work after updating their iPhones. This time, users all over the world were affected. In September, Abbott warned Apple users: "As part of the upcoming iOS 17 release, Apple is introducing StandBy Mode and Assistive Access Mode ... this release may impact your experience with the FreeStyle Libre 2 app, the FreeStyle LibreLink app, or the FreeStyle LibreLinkUp app. We recommend that you disable automatic operating system updates on the smartphone using the mentioned apps." This warning was made because StandBy Mode would sometimes prohibit time-sensitive notifications such as glucose alarms, and the Assistive Access Mode would impact sensor activation and alarm setting modification in the app...

And a scenario where a company abandons service or updates to its users is not merely theoretical. This is the bitter reality faced by users of eye implants produced by Second Sight Medical Products since the company decided to abandon the technology in 2020 when facing the prospect of bankruptcy. [">According to IEEE Spectrum], Terry Byland, whose sight has been dependent on the first-generation Argus implant since 2004, says of his experience, "As long as nothing goes wrong, I'm fine. But if something does go wrong with it, well, I'm screwed. Because there's no way of getting it fixed." That's what also happened to Barbara Campbell, whose retinal implant suddenly stopped working when she was on a subway...

It's up to us advocates of free software to inform the people around us of the issues with proprietary software in medical aids. Let's encourage our friends, parents, and grandparents to ask their doctor about the software in their medical devices and to choose and insist upon free software over proprietary software.

The Food and Drug Administration is warning consumers to ditch 26 over-the-counter eye drop products found at big retailers -- including CVS, Rite Aid, and Target -- due to a risk of infection. Consumers should not buy any of the products and should immediately stop using them if they've already purchased them. From a report: The products include Target's branded Up & Up Dry Eye Relief Lubricant Eye Drops and Up & Up Extreme Relief Dry Eye, as well as Lubricant Eye Drops and Lubricant Gel Drops branded by CVS Health and Rite Aid. The warning also includes eye drop products branded as Rugby and Leader (both from Cardinal Health) and Velocity Pharma. A full list can be found here, as can links to report adverse events.

In an advisory posted Friday, the FDA reported that no infections or adverse events have been linked to the products so far. But the agency said it "found insanitary conditions in the manufacturing facility and positive bacterial test results from environmental sampling of critical drug production areas in the facility."

Are face masks effective in stopping virus transmissions? CBS News re-visited the question Sunday on its news show 60 Minutes by sending their chief medical correspondent to interview Linsey Marr, a professor who specializes in aerosol science at Virginia Tech University.

Here's a transcript from an excerpt posted on YouTube: 60 Minutes: Is there any doubt in your mind that masks prevent the person who's wearing it from getting Covid — or at least, are helpful?

Professor Marr: I would say they are very helpful in reducing the chances that the person will get Covid. Because it's reducing the amount of virus that you would inhale from the air around you.

It's not going to guarantee that it's going to protect you, because are masks are not 100% effective — we talk about N-95's being 95% efficient at filtering out particles, if they're properly fitted and everything, and so that's in an ideal world. But even so, if you — instead of breathing in 100 virsues, I'm breathing in 20, because my mask was 80% effective? That's a huge reduction, and that greatly reduces the chance that I'm going to become infected.
On the CBS News web site, they highlight this excerpt from the interview: Early in the pandemic, some guidance from health professionals suggested that wearing a mask might actually lead to infection: A person might encounter a contaminated mask and then touch their eyes, nose, or mouth. But research in the ensuing years has shown that fear to be misplaced. "There wasn't any evidence really that that happens," Marr said.

Marr said her team aerosolized the coronavirus, pulled it through a mask, and then examined how much virus survived on the mask. The study reported some viral particle remained on some cloth masks, but no virus survived on the N95s or surgical masks. Marr's team also touched artificial skin to masks and looked at how many virus particles transferred to the artificial skin. No infectious virus transferred.

"I hope the study kind of shows that it's something we don't need to worry about as much as we were told," Marr said.
CBS gave their video interview the headline "Face mask effectiveness: What we know now" — and asked professor Marr for a definitive answer: 60 Minutes: There was a lot of controversy over whether or not masks worked at all. Were you able to show that they worked scientifically?

Professor Marr: We were able to show that they block particles that are the same size as those that carry the virus... What happens is the virus is being carried in the air, and it's not just going straight through those holes. It has to weave around all these layers of fibers in there. As the air is going around the curves, the virus may crash into one of those fibers, and so then it's trapped, or maybe it comes up close to the fiber and brushes against it. And the really small particles, like the virus by itself if it were by itself, would be small enough that it undergoes these random motions, because it's getting bounced around by the gas molecules, and it ends up crashing into the fibers of the mask too.

So there was accumulating evidence — and there had been kind of a handful of papers before that, too, showing the same thing. That masks — even cloth masks — do something.

An anonymous reader quotes a report from KOMO News: A groundbreaking medical procedure for those with kidney stones will soon be offered at the University of Washington after more than two decades of research. It will also give astronauts the go ahead they need from NASA to travel to Mars. It's a groundbreaking procedure to get rid of painful stones while you're awake, no anesthesia needed. "This has the potential to be game changing," said Dr. Kennedy Hall with UW Medicine. Still being run through clinical trials at UW Medicine, the procedure called burst wave lithotripsy uses an ultrasound wand and soundwaves to break apart the kidney stone. Ultrasonic propulsion is then used to move the stone fragments out, potentially giving patients relief in 10 minutes or less.

This technology is also making it possible for astronauts to travel to Mars, since astronauts are at a greater risk for developing kidney stones during space travel. It's so important to NASA, the space agency has been funding the research for the last 10 years. "They could potentially use this technology while there, to help break a stone or push it to where they could help stay on their mission and not have to come back to land," said Harper. The research has been published in the Journal of Urology.